Lonza Acquires Electroporation Company

Amaxa was founded in 1998 and employs 160 people. The company’s Nucleofection technology is nonviral transfection method that utilizes electroporation. After its purchase of Cambrex (see IBO 10/31/06), a cellular reagent provider, Lonza is adding instruments to its product line, gaining access to end-users and a technical expertise.

Basel, Switzerland 5/27/08—Lonza has acquired amaxa, a supplier of nucleic acid transfection systems and consumables, for an undisclosed amount. Amaxa will join the Cell Discovery business of Lonza Bioscience and its headquarters in Cologne, Germany, will become a new product development site for the Cell Discovery business. “With this acquisition Lonza further strengthens its position as a worldwide leader in cell discovery by integrating this unique, proprietary technology into its portfolio and by continuing to develop the activities in Cologne,” commented Lonza CEO Stefan Borgas. Lonza stated that amaxa’s Nucleofection technology for the transfection of primary cells compliments the company’s primary-cell production business.

< | >